SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Free Report) - Stock analysts at Zacks Small Cap issued their Q4 2025 earnings per share estimates for shares of SBC Medical Group in a research report issued to clients and investors on Wednesday, April 2nd. Zacks Small Cap analyst M. Marin forecasts that the company will post earnings per share of $0.07 for the quarter. The consensus estimate for SBC Medical Group's current full-year earnings is $5.02 per share.
SBC Medical Group Stock Down 2.5 %
SBC stock traded down $0.09 during midday trading on Thursday, reaching $3.32. 12,818 shares of the company were exchanged, compared to its average volume of 57,626. The company's 50-day moving average price is $4.19. SBC Medical Group has a 1-year low of $2.62 and a 1-year high of $12.50. The company has a current ratio of 2.79, a quick ratio of 2.76 and a debt-to-equity ratio of 0.06.
SBC Medical Group (NASDAQ:SBC - Get Free Report) last released its quarterly earnings data on Friday, March 28th. The company reported $0.18 EPS for the quarter, beating analysts' consensus estimates of $0.17 by $0.01. The business had revenue of $57.90 million during the quarter, compared to analysts' expectations of $56.34 million.
SBC Medical Group Company Profile
(
Get Free Report)
SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand.
See Also

Before you consider SBC Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SBC Medical Group wasn't on the list.
While SBC Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.